文献速递贫血与红细胞疾病

Sapablursen治疗非输血依赖型β地中海贫血中间型的2a期随机研究

Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia.
PubMed 文献 · Blood Adv · 2026-06-04

这项2a期研究评估了反义寡核苷酸sapablursen在非输血依赖型β地中海贫血中间型(NTDT)患者中的安全性、药代动力学和疗效。与既往研究不同,NTDT患者中相似剂量和暴露未导致血清hepcidin一致的剂量依赖性升高。

要点

  • Sapablursen在NTDT患者中总体安全耐受,但未达到升高血红蛋白或降低肝铁含量的终点。
  • NTDT患者中相似剂量和暴露未引起血清hepcidin一致的剂量依赖性升高。
  • 基线及研究期间肝铁含量和血清erythroferrone升高,可能阻碍通过TMPRSS6通路升高hepcidin。

核心结论

  • Sapablursen在NTDT患者中总体安全耐受,但未达到升高血红蛋白或降低肝铁含量的主要或次要终点。
  • NTDT患者中相似剂量和暴露未导致血清hepcidin一致的剂量依赖性升高,与既往健康志愿者和真性红细胞增多症患者中的观察不同。

研究设计与样本

  • 研究评估安全性、药代动力学和疗效,主要和次要终点包括升高血红蛋白和降低肝铁含量。

主要发现

  • Sapablursen总体安全且耐受良好。
  • 研究未达到升高血红蛋白或降低肝铁含量的主要或次要终点。
  • NTDT患者中相似剂量和暴露未导致血清hepcidin一致的剂量依赖性升高。
  • 基线和整个研究期间肝铁含量和血清erythroferrone均升高。

临床怎么用

  • Sapablursen在NTDT患者中未显示升高血红蛋白或降低肝铁含量的疗效,不支持在该人群中使用。
  • NTDT患者中hepcidin对TMPRSS6抑制的反应可能受基线肝铁含量和erythroferrone升高影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-transfusion-dependent b-thalassemia intermedia (NTDT) is a genetically heterogeneous disorder characterized by decreased β-globin production in erythroid cells resulting from mutations in the β-globin gene that is not treated with transfusion. NTDT is further characterized by a relative excess of a-globin which drives ineffective erythropoiesis resulting in increased iron absorption and ultimately iron overload. Sapablursen is an antisense oligonucleotide (ASO) that reduces the production of transmembrane protease serine 6 (TMPRSS6) and increases hepcidin production. This phase 2a study evaluated the safety, pharmacokinetics, and efficacy of sapablursen in patients with NTDT. Eligible patients had a clinical diagnosis of NTDT with genotypic confirmation of b-globin gene mutations. Twenty-nine patients with NTDT were treated with sapablursen at doses ranging from 30 to 160 mg once every 4 weeks (Q4W) for up to 2 years. Sapablursen was generally safe and well-tolerated. The study did not meet its primary or secondary endpoints of increased blood hemoglobin or reduced liver iron content (LIC). In earlier studies, including a phase 1 trial in healthy volunteers and a phase 2 trial in patients with polycythemia vera, sapablursen produced dose-dependent increases in serum hepcidin levels. However, in patients with non-transfusion-dependent thalassemia (NTDT), similar doses and exposures did not lead to consistent dose-dependent increases in serum hepcidin.. LIC and serum erythroferrone were elevated at baseline and throughout the current study. These two factors may prevent the elevation of serum hepcidin via the TMPRSS6 pathway. The companion article by Zhang et al. explores this mechanism in a mouse model of NTDT. Trial Registration Number: NCT04059406.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Taher A, Diamantidis MD, Kattamis A, et al. Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia. Blood Adv. 2026. PMID: 42241700. doi:10.1182/bloodadvances.2026019799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。